Patents by Inventor Geun-Seog Song

Geun-Seog Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230158001
    Abstract: The present invention relates to a pharmaceutical composition for preventing peptic ulcer and/or recurrence thereof containing a benzimidazole derivative. The pharmaceutical composition of the present invention may effectively prevent peptic ulcer and/or recurrence thereof, which may be caused by administration of a non-steroidal anti-inflammatory drug, for a long period of time without side effects.
    Type: Application
    Filed: April 13, 2021
    Publication date: May 25, 2023
    Inventors: Seokuee KIM, Yeong Hyeon JO, Eun Jee PARK, Bong Tae KIM, Heehyun KIM, Minja KANG, Geun Seog SONG, Naree SHIN, Eun Ji KIM, Eunbi CHO
  • Publication number: 20220125764
    Abstract: The present invention relates to a pharmaceutical composition for preventing the recurrence of gastroesophageal reflux disease, comprising a benzimidazole derivative. The pharmaceutical composition of the present invention may effectively prevent the recurrence of gastroesophageal reflux disease without any side effects for a long period of time.
    Type: Application
    Filed: February 17, 2020
    Publication date: April 28, 2022
    Applicant: HK INNO.N CORPORATION
    Inventors: Bong Tae KIM, Hyun Kyung LEE, Ji Yeon NAM, Mi Hwa OH, Geun Seog SONG, Myeongjoong KIM
  • Publication number: 20210196685
    Abstract: The present invention relates to a composition for eradicating Helicobacter pylori and a use thereof. The composition of the present invention maintains an intragastric pH at a certain level or more for a certain period of time or longer, thereby maximizing an action of amoxicillin and clarithromycin to show an excellent effect on eradicating Helicobacter pylori.
    Type: Application
    Filed: August 28, 2019
    Publication date: July 1, 2021
    Applicant: HK INNO.N CORPORATION
    Inventors: Bong Tae KIM, Dongkyu KIM, Eun Ji KIM, Ji Won LEE, Kyeongmin OH, Ahrong KIM, Geun Seog SONG, Shin-Young RYU, Eun Kyung KIM, Naree SHIN, Hyun Ji KANG, Jae Min KIM, Yu-Gyeong PARK, Haneul JEONG
  • Patent number: 11033532
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can more effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: June 15, 2021
    Assignee: HK INNO.N CORPORATION
    Inventors: Ha Jin Lee, Bong Tae Kim, Hyun Kim, Ji Yeon Nam, Jie Eun Park, Geun Seog Song, Shin Young Ryu, Shinichi Koizumi, Nobuyuki Takahashi, Masaomi Tajimi
  • Publication number: 20200069652
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can more effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 5, 2020
    Applicants: CJ HEALTHCARE CORPORATION, RaQualia Pharma Inc.
    Inventors: Ha Jin LEE, Bong Tae KIM, Hyun KIM, Ji Yeon NAM, Jie Eun PARK, Geun Seog SONG, Shin Young RYU, Shinichi KOIZUMI, Nobuyuki TAKAHASHI, Masaomi TAJIMI
  • Patent number: 10512635
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can mere effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: December 24, 2019
    Assignees: CJ Healthcare Corporation, RaQualia Pharma Inc.
    Inventors: Ha Jin Lee, Bong Tae Kim, Hyun Kim, Ji Yeon Nam, Jie Eun Park, Geun Seog Song, Shin Young Ryu, Shinichi Koizumi, Nobuyuki Takahashi, Masaomi Tajimi
  • Publication number: 20180338954
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can mere effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Application
    Filed: June 8, 2016
    Publication date: November 29, 2018
    Applicants: CJ HEALTHCARE CORPORATION, RaQualia Pharma Inc.
    Inventors: Ha Jin LEE, Bong Tae KIM, Hyun KIM, Ji Yeon NAM, Jie Eun PARK, Geun Seog SONG, Shin Young RYU, Shinichi KOIZUMI, Nobuyuki TAKAHASHI, Masaomi TAJIMI
  • Patent number: 9592262
    Abstract: The present invention relates to a composition including a Laurus nobilis leaf extract as an active ingredient, and particularly, to a composition for preventing or treating hangover including the Laurus nobilis leaf extract, a food composition for preventing or relieving hangover including the Laurus nobilis leaf extract, and a method for preparing the composition. Since the composition according to the present invention includes the Laurus nobilis leaf extract, it has a remarkably excellent effect of lowering blood concentrations of alcohol and acetaldehyde. Its hangover-preventing and treating effects were confirmed by behavioral tests, and thus the composition can be widely applied to foods, drugs, or functional health foods which can be effectively used for preventing and treating hangover.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: March 14, 2017
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Se Hee Paek, Byoung Seok Moon, Seok Jun Park, Yong Ki Seo, Geun Seog Song
  • Publication number: 20140314887
    Abstract: The present invention relates to a composition including a Laurus nobilis leaf extract as an active ingredient, and particularly, to a composition for preventing or treating hangover including the Laurus nobilis leaf extract, a food composition for preventing or relieving hangover including the Laurus nobilis leaf extract, and a method for preparing the composition. Since the composition according to the present invention includes the Laurus nobilis leaf extract, it has a remarkably excellent effect of lowering blood concentrations of alcohol and acetaldehyde. Its hangover-preventing and treating effects were confirmed by behavioral tests, and thus the composition can be widely applied to foods, drugs, or functional health foods which can be effectively used for preventing and treating hangover.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Applicant: CJ CHEILJEDANG CORPORATION
    Inventors: Se Hee PAEK, Byoung Seok MOON, Seok Jun PARK, Yong Ki SEO, Geun Seog SONG
  • Patent number: 7776873
    Abstract: Provided is a method for treating damage to the gastric mucosa with a cytoprotective agent, comprising administering to a human in need thereof a pharmaceutical composition comprising an effective amount for treating damage to gastric mucosa of a pharmaceutically acceptable salt of revaprazan as the cytoprotective agent, and a pharmaceutically acceptable carrier. Revaprazan or its salt has an excellent treatment effect for gastrointestinal mucosal damage by potentiating a defensive factor in the gastrointestinal mucosa, simultaneously with acting as an acid pump antagonist.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: August 17, 2010
    Assignee: Yuhan Corporation
    Inventors: Ki-Baik Hahm, Dong-Kyu Kim, Mi-Sun Kwak, Sang-Aun Joo, Byoung-Seok Moon, Geun-Seog Song
  • Publication number: 20070129391
    Abstract: Provided is a composition for preventing or treating damages of the mucosa in the gastrointestinal tracts, comprising revaprazan or a salt thereof and a pharmaceutically acceptable carrier. Revaprazan or its salt has an excellent preventive or treatment effect for gastrointestinal mucosal damage by potentiating a defensive factor in the gastrointestinal mucosa, simultaneously with acting as an acid pump antagonist.
    Type: Application
    Filed: November 27, 2006
    Publication date: June 7, 2007
    Applicant: Yuhan Corporation
    Inventors: Ki-Baik Hahm, Dong-Kyu Kim, Mi-Sun Kwak, Sang-Aun Joo, Byoung-Seok Moon, Geun-Seog Song